Apellis Pharmaceuticals, Inc.

APLS

US03753U1060

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:35:45 28/05/2024 pm IST			5-day change	1st Jan Change
40.13 ^USD	-1.18%		-5.19%	-32.59%

24/05	Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases	MT
24/05	Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress	CI

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

December 14, 2023 at 05:34 pm IST

On December 14, 2023, Apellis Pharmaceuticals, Inc. (?Apellis?) provided an update on the ongoing review of its marketing authorization application, or MAA, for intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration by the Committee for Medicinal Products for Human Use, or the CHMP, of the European Medicines Agency.

Latest news about Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases	24/05	MT
Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress	24/05	CI
Wells Fargo Adjusts Price Target on Apellis Pharmaceuticals to $48 From $57, Maintains Equal-Weight Rating	24/05	MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM	14/05
Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street	14/05	MT
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street	14/05	CI
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing	10/05	MT
UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating	08/05	MT
Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating	08/05	MT
Transcript : Apellis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	07/05
Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises	07/05	MT
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q1 Revenue $172.3M	07/05	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating	29/04	MT
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment	26/04	MT
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency	26/04	CI
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating	17/04	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	10/04	MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM	08/04
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	21/03	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	20/03	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing	15/03	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing	12/03	MT
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024	11/03	CI
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating	06/03	MT

Chart Apellis Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Companyâs approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Sector

Pharmaceuticals

Calendar

05/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Apellis Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.61 USD

Average target price

79.5 USD

Spread / Average Target

+95.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
APELLIS PHARMACEUTICALS, INC.	-32.59%	492.87Cr
CSL LIMITED	-1.64%	9.03TCr
SAMSUNG BIOLOGICS CO.,LTD.	-1.97%	3.95TCr
BIOGEN INC.	-16.12%	3.17TCr
UCB	+61.28%	2.64TCr
BIOMARIN PHARMACEUTICAL INC.	-22.79%	1.43TCr
INCYTE CORPORATION	-9.16%	1.29TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.77%	1.18TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.97%	1.1TCr
SWEDISH ORPHAN BIOVITRUM AB	+3.30%	884.67Cr

Biopharmaceuticals